News

Date Title View
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Huan Sheng, M.D., Ph.D., as Director Clinical Research and Drug Safety
IRVINE, Calif. --(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the appointment
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Barry Ivin as Site Director of New Manufacturing Plant in Ireland
IRVINE, Calif. --(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the appointment
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Kristine Erickson, O.D., Ph.D., as Vice President Clinical Research
IRVINE, Calif. --(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the appointment
View HTML
Toggle Summary Aerie Pharmaceuticals Enters into Lease Agreement for New Manufacturing Plant in Ireland
IRVINE, Calif. --(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced that it has
View HTML
Toggle Summary Aerie Pharmaceuticals Provides Update on Timing of NDA Filing for RhopressaTM (netarsudil ophthalmic solution) 0.02%
IRVINE, Calif. --(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today reported that it has been
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Judith J. Robertson as Chief Commercial Officer
IRVINE, Calif. --(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the appointment
View HTML
Toggle Summary Aerie Pharmaceuticals Completes Enrollment of Mercury 2 Phase 3 Registration Trial of Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%
- Trial On Track for Topline 90-day Efficacy Readout in Q2 2017 - IRVINE, Calif. --(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced
View HTML
Toggle Summary Aerie Pharmaceuticals to Participate in Two Investor Conferences in December
IRVINE, Calif. --(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that company management will participate in the following
View HTML
Toggle Summary Aerie Pharmaceuticals to Participate in Three Investor Conferences in November
IRVINE, Calif. --(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that company management will present an overview of the company at
View HTML
Toggle Summary Aerie Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Business Update
- New Data Adds Further Positive Insight into Rhopressa TM and Roclatan TM Potential - - Company Closes the Third Quarter with Over $255 million in Cash and Investments - Conference Call and Webcast Today, November 2 , at 5:00 p.m. ET IRVINE, Calif. --(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc.
View HTML